The receptor concept: A continuing evolution

Molecular Interventions

Volumn 4, Issue 6, 2004, Pages 326-336

  Limbird, Lee E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENYLATE CYCLASE; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOTROPIN RECEPTOR; CYCLIC AMP; EZRIN; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RADIOLIGAND; RECEPTOR ACTIVITY MODIFYING PROTEIN; RETINA S ANTIGEN; SODIUM PROTON EXCHANGE PROTEIN; SPINOPHILIN;

ENZYME ACTIVITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIGAND BINDING; MOLECULAR CLONING; MOLECULAR MODEL; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 12344321686     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.6.6     Document Type: Review

References (95)

1. Erhlich, P. Chemotherapeutics: Scientific principles, methods and results. Lancet 2, 445-451 (1913).
2. Langley, J.N. On the contraction of muscle, chiefly in relation to the presence of "receptive" substances. Part IV. The effect of curare and of some other substances on the nicotine response of the sartorius and gastrocnemius muscles of the frog. J. Physiol. 39 235-295 (1909).
3. Dale, H.H. The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharm. Exp. Ther. 6 174-190 (1914).
4. Ahlquist, R.P. A study of the adrenotropic receptors. Am. J. Physiol. 155, 586-600 (1948).
5. Ahlquist, R.P. Historical perspective. Classification of adrenoreceptors. J. Auton. Pharmacol. 1, 101-106 (1980).
6. Clark, A.J. The reaction between acetyl choline and muscle cells. Part II. J. Physiol. 64, 123-143 (1927).
7. Stephenson, R.P. A modification of receptor theory. Br. J. Pharm. 11, 379-393 (1956).
8. Furchgott, R.F. and Bhadrakom, S. Reactions of strips of rabbit aorta to epinephrine, isoproterenol, sodium nitrite and other drugs. J. Pharm. Exp. Ther. 108, 129-143 (1953).
9. Nickerson, M. Receptor occupancy and tissue response. Nature 78, 697-698 (1956).
10. Arunlakshana, O. and Schild, H.O. Some quantitative uses of drug antagonists. Brit. J. Pharm. 14, 48-58 (1959).
11. Lefkowitz, R.J., Roth, J. Pricer, W., and Pastan, I. ACTH receptors in the adrenal: Specific binding of ACTH-1251 and its relation to adenyl cyclase. Proc. Natl. Acad. Sci. U.S.A. 65, 745-752 (1970).
12. Lefkowitz, R.J. and Haber, E. A fraction of the ventricular myocardium that has the specificity of the cardiac β-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 68, 1773-1777 (1971).
13. 3H-(-)-alprenolol binding sites, β -adrenergic receptors and adenylate cyclase. Biochem. Biophys. Res. Commun. 60, 703-709 (1974).
14. Aurbach, G.D., Fedak, S.A., Woodard, C.J., Palmer, J.S., Hauser, D., and Troxler, F. β-Adrenergic receptor: Stereospecific interaction of iodinated β-blocking agent with high affinity site. Science 186, 1223-1224 (1974).
15. Levitzki, A., Atlas, D., and Steer, M.L. The Binding Characteristics and Number of β-Adrenergic Receptors on the Turkey Erythrocyte. Proc. Natl. Acad. Sci. U.S.A. 71, 2773-2776 (1974).
16. U'Prichard, D.C., Greenberg, D.A., and Snyder, S.H. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system α noradrenergic receptors. Mol. Pharm. 13, 454-473 (1977).
17. U'Prichard, D.C., Charness, M.E., Robertson, D., and Snyder, S.H. Prazosin: Differential affinities for two populations of (α-noradrenergic receptor binding sites. Eur. J. Pharm. 50, 87-89 (1978).
18. U'Prichard, D.C. and Synder, S.H. Distinct α-noradrenergic receptors differentiated by binding and physiological relationships. Life Sci. 24, 79-88 (1979).
19. Lefkowitz, R.J. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends Pharm. Sci. 25, 413-422 (2004).
20. Sutherland, E.W. and Rall, T.W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232, 1077-1091 (1958).
21. Sutherland, E.W., Rall, T.W., and Menon, T. Adenyl cyclase. I. Distribution, preparation, and properties. J. Biol. Chem. 237 1220-1227 (1962).
22. Robison, G.A., Butcher, R.W., and Sutherland, E.W. Adenyl cyclase as an adrenergic receptor. Ann. N.Y. Acad. Sci. 139, 703-723 (1967).
23. Orly, J. and Schramm, M. Coupling of catecholamine receptor from one cell with adenylate cyclase from another cell by cell fusion. Proc. Natl. Acad. Sci. U.S.A. 73, 4410-4414 (1976).
24. Limbird, L.E. and Lefkowitz, R.J. Resolution of β-adrenergic receptor binding and adenylate cyclase activity by gel exclusion chromatography. J. Biol. Chem. 252, 799-802 (1977).
25. Vauqelin, G., Geynet, P., Hanoune, J., and Strosberg, A.D. Isolation of adenylate cyclase-free, β-adrenergic receptor from turkey erythrocyte membranes by affinity chromatography. Proc. Natl. Acad. Sci. U.S.A. 74, 3710-3714 (1977).
26. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Krans, H.M. The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J. Biol. Chem. 246, 1877-1882 (1971).
27. Pfeuffer, T. GTP-binding proteins in membranes and the control of adenylate cyclase activity. J. Biol. Chem. 252, 7224-7234 (1977).
28. Ross, E.M. and Gilman, A.G. Resolution of some components of adenylate cyclase necessary for catalytic activity. J. Biol. Chem. 252, 6966-6969 (1977).
29. Ross, E.M., Maguire, M.E., Sturgill, T.W., Biltonen, R.L., and Gilman, A.G. Relationship between the β-adrenergic receptor and adenylate cyclase. J. Biol. Chem. 252, 5761-5775 (1977).
30. Cassel, D. and Selinger, Z. Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim. Biophys. Acta. 452, 538-551 (1976).
31. Cassel, D. and Selinger, Z. Mechanism of aderrylate cyclase activation by cholera toxin: Inhibition of GTP hydrolysis at the regulatory site. Proc. Natl. Acad. Sci. U.S.A. 74, 3307-3311 (1977).
32. Cassel, D. and Selinger Z. Mechanism of adenylate cyclase activation through the β-adrenergic receptor: Catecholamine-induced displacement of bound GDP by GTP. Proc. Natl. Acad. Sci. U.S.A. 75, 4155-4159 (1978).
33. Gilman, A.G. G proteins: Transducers of receptor generated signals. Annu. Rev. Biochem. 56, 615-649 (1987).
34. Limbird, L.E., Gill, D.M., and Lefkowitz, R.J. Agonist-promoted coupling of the β-adrenergic receptor with the guanine nucleotide regulatory protein of the adenylate cyclase system. Proc. Natl. Acad. Sci. U.S.A. 77, 775-779 (1980).
35. Hepler, J.R. and Gilman, A.G. G proteins. Trends Biochem. Sci. 17, 383-387 (1992).
36. Maguire, M.E., Van Arsdale, P.M., and Gilman, A.G. An agonist-specific effect of guanine nucleotides on binding to the β adrenergic receptor. Mol. Pharm. 12, 335-339 (1976).
37. Lefkowitz, R.J., Mullikin, D., and Caron, M.G. Regulation of β-adrenergic receptors by guanyl-5′-yl imidodiphosphate and other purine nucleotides. J. Biol. Chem. 251, 4686-4692 (1976).
38. Burgisser, E., De Lean, A., and Lefkowitz, R.J. Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc. Natl. Acad. Sci. U.S.A. 79 1732-1736 (1982).
39. Flier, J.S., Kahn, C.R., Jarrett, D.B., and Roth, J. The immunology of the insulin receptor. Immunol. Commun. 5, 361-373 (1976).
40. Jahns, R., Boivin, V., Hein, L., Triebel, S., Angermann, C.E., Ertl, G., and Lohse, M.J. Direct evidence for a b1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest. 113, 1419-1429 (2004).
41. Freedman, N.J. and Lefkowitz, R.J. Anti-b1-adrenergic receptor antibodies and heart failure: Causation, not just correlation. J. Clin. Invest. 113, 1379-1382 (2004).
42. Clapham, D.E. Mutations in G protein-linked receptors: Novel insights on disease, Cell 75, 1237-1239 (1993).
43. 1-adrenergic receptor determine the selectivity of coupling to phosphatidylinositol hydrolysis. J. Biol. Chem. 267, 1633-1639 (1992).
44. Jacobs, S. and Cuatrecasas, P. The mobile receptor hypothesis and "cooperativity" of hormone binding: Application to insulin. Biochim. Biophys. Acta. 433, 482-495 (1976).
45. DeHaen, C. The non-stoichiometric floating receptor model for hormone sensitive adenylyl cyclase. J. Theoret. Biol. 58, 383-400 (1976).
46. Tolkovsky, A.M., Braun, S., and Levitzki, A. Kinetics of interaction between β-receptors, GTP protein, and the catalytic unit of turkey erythrocyte adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 79, 213-217 (1982).
47. De Lean, A., Stadel, J.M., and Lefkowitz, R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-receptor. J. Biol. Chem. 255, 7108-7117 (1980).
48. Wreggett, K.A. and De Lean, A. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. Mol. Pharm. 26, 214-227 (1984).
49. 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636 (1993).
50. Weiss, J.M., Morgan, P.H., Lutz, M.W., and Kenakin, T.P. The cubic ternary complex receptor-occupancy model. I. Model description. J. Theor. Biol. 178, 151-167 (1996).
51. Hall, D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol. Pharm. 58, 1412-1423 (2000).
52. Christopoulos, A. and Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
53. Kenakin, T. Principles: Receptor theory in pharmacology. Trends Pharm. Sci. 25, 186-192 (2004).
54. Perez, D.M., Hwa, J., Gaivin, R., Mathur, M., Brown, F., and Graham, R.M. Constitutive activation of a single effector pathway: Evidence for multiple activation sites of a G protein-coupled receptor. Mol. Pharm. 49, 112-122 (1996).
55. 2-adrenergic receptor. J. Biol. Chem. 276, 24433-24436 (2001).
56. Seifert, R., Wenzel-Seifert, K., Gether, U., and Kobilka, B.K. Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations. J. Pharm. Exp. Ther. 297, 1218-1226 (2001).
57. Gether, U. and Kobilka, B.K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979-17982 (1998).
58. Kobilka, B.K. Agonist binding: A multi-step process. Mol. Pharm. 65, 1060-1062 (2004).
59. 2 adrenergic receptor. Mol. Pharm. 65, 1181-1190 (2004).
60. Kenakin, T. Ligand-selective receptor conformations revisited: The promise and the problem. Trends Pharmacol. Sci. 24, 346-354 (2003).
61. Kenakin, T. Agonist-receptor efficacy II: Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232-238 (1995).
62. Mukherjee, C., Caron, M.G., and Lefkowitz, R.J. Catecholamine-induced subsensitivity of adenylate cyclase associated with loss of β-adrenergic receptor binding sites. Proc. Natl. Acad. Sci. U.S.A. 72, 1945-1949 (1975).
63. Harden, T.K., Cotton, C.U., Waldo, G.L., Lutton, J.K., and Perkins, J.P. Catecholamine-induced alteration in sedimentation behavior of membrane bound β-adrenergic receptors. Science 210, 441-443 (1980).
64. Su, Y.F., Harden, T.K., and Perkins, J.P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J. Biol. Chem. 255, 7410-7419 (1980).
65. Hausdorff, W.P., Caron, M.G., and Lefkowitz, R.J. Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J. 4, 2881-2889 (1990).
66. Lefkowitz, R.J. G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273, 18677-18680 (1998).
67. Luttrell, L.M. and Lefkowitz, R.J. The role of β-arrestins in the termination and transduction of G protein-coupled receptor signals. J. Cell Sci. 115, 455-465 (2002).
68. Sorkin, A. and Von Zastrow, M. Signal transduction and endocytosis: Close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 3, 600-614 (2002).
69. Kouhout, T.A. and Lefkowitz, R.J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9-18 (2003).
70. 2-adrenergic receptor subtypes in cells and tissues. Pharmacol. Ther. 84, 193-205 (1999).
71. Shorr, R.G., Lefkowitz, R.J., and Caron, M.G. Purification of the β-adrenergic receptor. Identification of the hormone binding subunit. J. Biol. Chem. 256, 5820-5826 (1981).
72. Shorr, R.G., Strohsacker, M.W., Lavin, T.N., Lefkowitz, R.J., and Caron, M.G. The β1-adrenergic receptor of the turkey erythrocyte. Molecular heterogeneity revealed by purification and photoaffinity labeling. J. Biol. Chem. 257, 12341-12350 (1982).
73. Homcy, C.J., Rockson, S.G., Countaway, J., and Egan, D.A. Purification and characterization of the mammalian β2-adrenergic receptor. Biochemistry 22, 660-668 (1983).
74. Benovic, J.L., Shorr, R.G., Caron, M.G., and Lefkowitz, R.J. The mammalian β2-adrenergic receptor: Purification and characterization. Biochemistry 25, 4510-4518 (1984).
75. Dixon, R.A., Kobilka, B.K., Strader, D.J. et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature 321, 75-79 (1986).
76. 2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 240, 1310-1316 (1988).
77. Yin, D., Gavi, S., Wang, H.Y., and Malbon, C.C. Probing receptor structure/function with chimeric G-protein-co-receptors. Mol. Pharmacol. 65, 1323-1332 (2004). Erratum Mol. Pharm. 66 198 (2004).
78. Starke, K. α-Adrenoceptor subclassification. Rev. Physiol. Biochem. Pharmacol. 88, 199-236 (1981).
79. 2-adrenoceptor-subtype function. Trends Pharm. Sci. 18, 211-219 (1997).
80. Rohrer, D.K. and Kobilka, B.K. Insights from in vivo modification of adrenergic receptor gene expression. Annu. Rev. Pharmacol. Toxicol. 38, 351-373 (1998).
81. 2-adrenergic receptors. J. Pharm. Exp. Ther. 293, 1-7 (2000).
82. Ross, E.M. Signal Sorting and Amplification through G Protein-Coupled Receptors. Neuron 3, 141-152 (1989).
83. Weng, G., Bhalla, U.S., and Iyengar, R. Complexity in biological systems. Science 284, 92-96 (1999).
84. Neves, S.R., Ram, P.T., and Iyengar, R. G protein pathways. Science 296, 1636-1639 (2002).
85. Blumer, J.B. and Lanier, S.M. Accessory proteins for G protein-signaling systems: Activators of G protein signaling and other nonreceptor proteins influencing the activation state of G proteins. Receptors Channels 9, 195-204 (2003).
86. Neubig, R.R. and Siderovski, D.P. Regulators of G-protein signalling as new central nervous system drug targets. Nat. Rev. Drug Disc. 1, 187-197 (2002).
87. B Receptors. Physiol. Rev. 84, 835-867 (2003).
88. Jordan, B.A. and Devi, L.A. G protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (1999).
89. Hay, D.L., Conner, A.C., Howitt, S.G., Smith, D.M., and Poyner, D.R. The pharmacology of adrenomedullin receptors and their relationships to CGRP receptors. J. Mol. Neurosci. 22, 105-113 (2004).
90. Shenoy, S.K. and Lefkowitz, R.J. Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem. J. 375, 503-515 (2003 ).
91. Wang, Q., Zhao, J., Brady, A.E., Feng, J., Allen, P.B., Lefkowitz, R.J., Greengard, P., and Limbird, L.E. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304, 1940-1944 (2004).
92. Lau, A.G. and Hall, R.A. Oligomerization of NHERF-1 and NHERF-2 PDZ domains: Differential regulation by association with receptor carboxyl-termini and by phosphorylation. Biochemistry 40, 8572-8580 (2001).
93. Cao, T.T., Deacon, H.W., Reczek, D., Bretscher, A., and von Zastrow, M. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the β2-adrenergic receptor. Nature 401, 286-290 (1999).
94. Von Zastrow, M. Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. Life Sci. 74, 217-224 (2003).
95. Brady, A.E. and Limbird, L.E. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cell Signal. 14, 297-309 (2002).